| Labcorp

September 28, 2023

End-to-end drug and diagnostic development support for an immuno-oncology agent

Immuno-oncology drug development is inherently complex and requires special considerations across the entire spectrum, from preclinical to commercial support for the approved product.

September 28, 2023

Cell and gene therapy: Overview, current landscape and future trends

This white paper provides an engaging background on cell and gene therapies, a look into recent therapeutic applications and future trends in the cell and gene therapy technology space.

September 28, 2023

Cell therapy for treatment of cancer

This white paper provides the current position on the key cell types and their role in cancer immunotherapies, with a more in-depth focus on chimeric antigen receptor (CAR) T-cell therapies.

October 3, 2023

Nonclinical considerations for cell and gene therapies

With nearly a dozen or more products commercialized globally and approximately 1000 clinical trials underway as of the end of 2018, cell and gene therapies are significant component for drug development.

<span>Second generation mRNA Marburg vaccine: Formulation development of mRNA-lipid nanoparticles with TLR9 agonist CpG oligonucleotide adjuvant</span>

October 4, 2023

Second generation mRNA Marburg vaccine: Formulation development of mRNA-lipid nanoparticles with TLR9 agonist CpG oligonucleotide adjuvant

CPI RNA Vaccines 2023 -- A vaccine against Marburg virus is being developed using a self-amplifying messenger RNA (sa mRNA) for the Marburg Glycoprotein (MARV GP) antigen. The vaccine comprises the sa mRNA encapsulated into a lipid nanoparticle (LNP) for protection of the RNA and cellular delivery.

October 4, 2023

Rational selection of Toll-like receptor agonists (TLR) for the development of Marburg vaccine formulation

CPI RNA Vaccines 2023 -- Marburg virus infection causes haemorrhagic fever with fatality rates of up to 88%. Provision of a vaccine to Marburg virus is an unmet medical need.

October 4, 2023

A basic overview of hemocompatibility

Hemocompatibility refers to the ability of a device to cause hemolysis (rupture of red blood cells), clotting, formation of a thrombus or activation of the complement system. Hemocompatibility testing is essential for evaluating the interactions of medical devices having contact with blood.

<span>In vitro cytotoxicity and mechanistic insight from MucilAir™ and SmallAir™ tissues exposed to cigarette smoke and next-generation products</span>

October 8, 2023

In vitro cytotoxicity and mechanistic insight from MucilAir™ and SmallAir™ tissues exposed to cigarette smoke and next-generation products

Coresta SSPT 2023 -- This study was a proof of concept suggesting that MucilAir™ tissues can be used to differentiate between combustible cigarettes or HTP and ENDS products with regards to cytotoxicity assessment. These tissues are also useful in elucidating pathways of cytotoxicity.

<span>In vitro micronucleus in V79 cells using MicroFlow - Treatment at the air liquid interface with aerosol from three different nicotine containing products</span>

October 8, 2023

In vitro micronucleus in V79 cells using MicroFlow - Treatment at the air liquid interface with aerosol from three different nicotine containing products

Coresta SSPT 2023 -- Assays for the detection of chromosome damage in mammalian cells cultured in vitro are recommended in regulatory guidelines as a complement to Ames tests in a genotoxicity test battery. An alternative to measuring structural aberrations in mitotic cells is to measure micronuclei.

<span>Validation of the Vitrocell® HTP 2.0+ 12-well mammalian module for assessing cigarettes, ENDS and eHTPs: Evaluation of dilution airflow, dose resolution and dose repeatability</span>

October 8, 2023

Validation of the Vitrocell® HTP 2.0+ 12-well mammalian module for assessing cigarettes, ENDS and eHTPs: Evaluation of dilution airflow, dose resolution and dose repeatability

Coresta SSPT 2023 -- The present study aimed to validate the performance of the Vitrocell® HTP 2.0+ 12-well mammalian module for assessing three different test articles: cigarettes, electronic nicotine delivery systems (ENDS) and electronic tobacco heated products (eHTPs).

管理您的健康

疾病与治疗领域

治疗模式与方法

科学实验室学科

实验室

行业

End-to-end drug and diagnostic development support for an immuno-oncology agent

Cell and gene therapy: Overview, current landscape and future trends

Cell therapy for treatment of cancer

Nonclinical considerations for cell and gene therapies

Second generation mRNA Marburg vaccine: Formulation development of mRNA-lipid nanoparticles with TLR9 agonist CpG oligonucleotide adjuvant

Rational selection of Toll-like receptor agonists (TLR) for the development of Marburg vaccine formulation

A basic overview of hemocompatibility

In vitro cytotoxicity and mechanistic insight from MucilAir™ and SmallAir™ tissues exposed to cigarette smoke and next-generation products

In vitro micronucleus in V79 cells using MicroFlow - Treatment at the air liquid interface with aerosol from three different nicotine containing products

Validation of the Vitrocell® HTP 2.0+ 12-well mammalian module for assessing cigarettes, ENDS and eHTPs: Evaluation of dilution airflow, dose resolution and dose repeatability